The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2023 | Current and emerging treatment strategies for post-MPN AML
Pankit Vachhani, MD, University of Alabama at Birmingham, Birmingham, AL, discusses the biology and treatment of acute myeloid leukemia (AML) arising from a previous myeloproliferative neoplasm (MPN). Current treatments usually require intensive chemotherapy or hypomethylating agents (HMAs). Dr Vachhani discusses the potential of allogeneic stem cell transplantation (alloSCT) and provides insight into novel disease-modifying drugs under investigation for the treatment of these patients. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
